-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 6, Moderna announced its 2021 Q2 financial report.
The total revenue for the second quarter was 4.
4 billion U.
S.
dollars and the net income was 2.
8 billion U.
S.
dollars
.
The financial report shows that Moderna has a R&D pipeline layout in the fields of COVID-19, infectious diseases, autoimmune diseases, and tumor diseases.
There are 23 mRNA development projects in its product portfolio, 15 of which have entered clinical research
According to the financial report data, Moderna has obtained emergency authorization from health institutions in more than 50 countries/regions to vaccinate adults with its COVID-19 vaccine, and has also obtained the World Health Organization (WHO) Emergency Use List (EUL), as well as in the European Union.
And Japan’s authorization to use its COVID-19 vaccine among adolescents 12 years and older
.
In this financial report, Moderna updated the clinical data of its COVID-19 vaccine.
In the final analysis of the COVE Phase 3 study data, the Moderna COVID-19 vaccine showed a protective effect of 93%.
At the same time, after the second vaccination Within six months, its effectiveness remains long-lasting
.
Image source: Moderna 2021 Q2 financial report
In addition, for the currently concerned strain variants, in its phase 2 clinical study, Moderna's three candidate mRNA boosters can induce wild-type D614G COVID-19 strains, Gamma (P.
1) Beta (B.
1.
351), Delta (B.
1.
617.
2) produced strong antibody responses, and the three candidate booster needles were mRNA-1273, mRNA-1273.
351 and mRNA-1273.
211
.
For the candidate booster mRNA-1273, the financial report disclosed some of the latest data.
Six months after the second true vaccination, the neutralizing antibody of the vaccine against the wild-type D614G COVID-19 strain can still maintain a high level, but it is against the mutant strain.
Neutralizing antibodies showed a downward trend
.
However, after inoculation with a dose of 50 μg mRNA-1273 booster, the levels of neutralizing antibodies against the other three major new crown variants were significantly increased
.
Image source: Moderna 2021 Q2 financial report
Moderna mentioned in its financial report that the current data can support a dose of 50 μg of mRNA-1273 as a booster shot for COVID-19 vaccine.
Note: The original text has been deleted
Reference materials:
[1]https://investors.
[2]https://investors.
